Literature DB >> 23390018

Biosimilars in rheumatology: the wind of change.

Christian K Schneider.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23390018     DOI： 10.1136/annrheumdis-2012-202941

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  36 in total

1.  [Regulatory aspects of biosimilars. Myths and facts].

Authors:  C K Schneider; M Weise
Journal:  Z Rheumatol       Date:  2015-10       Impact factor: 1.372

Review 2.  Biosimilars in rheumatology: current perspectives and lessons learnt.

Authors:  Thomas Dörner; Jonathan Kay
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

3.  [Implementation and use of biosimilars in the therapy of inflammatory rheumatic diseases: Statement of the German Society of Rheumatology].

Authors:  H-M Lorenz; J Braun; K Krüger; M Schneider
Journal:  Z Rheumatol       Date:  2014-11       Impact factor: 1.372

Review 4.  Biosimilars: clinical interpretation and implications for drug development.

Authors:  Eduardo Mysler
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

Review 5.  Update on biosimilars in rheumatology.

Authors:  Adam Rischin; Andrew J K Östör
Journal:  Inflammopharmacology       Date:  2017-03-07       Impact factor: 4.473

6.  Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today?

Authors:  Stanton R Mehr; Marj P Zimmerman
Journal:  Am Health Drug Benefits       Date:  2016-12

Review 7.  Biosimilars in IBD: from theory to practice.

Authors:  Silvio Danese; Stefanos Bonovas; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

8.  Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis.

Authors:  Kuttipurath Kandi Roshique; Vinod Ravindran
Journal:  Clin Rheumatol       Date:  2015-06-03       Impact factor: 2.980

9.  Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.

Authors:  Morgane Beck; Bruno Michel; Marie-Christine Rybarczyk-Vigouret; Dominique Levêque; Christelle Sordet; Jean Sibilia; Michel Velten
Journal:  MAbs       Date:  2016-12-08       Impact factor: 5.857

10.  Position of the Canadian Association of Gastroenterology on subsequent entry biologics is challenged by biosimilar industry representatives.

Authors:  Miklos Sebeszta; Alex Kudrin
Journal:  Can J Gastroenterol Hepatol       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.